Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lomvastomig - Roche

Next Previous
Drug Profile

Lomvastomig - Roche

Alternative Names: anti-PD-1/TIM-3 bispecific antibody - Roche; Lomvastomig; PD1-TIM3 BsAb; RG-7769; RO-7121661

Latest Information Update: 13 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Roche
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Oesophageal cancer
  • No development reported Malignant melanoma; Non-small cell lung cancer; Solid tumours

Most Recent Events

  • 30 Jan 2025 Roche completes a phase II trial Oesophageal cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in Argentina, Germany, Brazil, Czechia, Denmark, France, Hungary, Italy, Kenya, South Korea, Poland, Russia, Singapore, Spain, Taiwan, Thailand, Turkey, Ukraine and United Kingdom(IV) (NCT04785820) (EudraCT-2020-004606-60)
  • 28 Oct 2024 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease, Second-line therapy or greater) in Denmark (IV)
  • 28 Oct 2024 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease, Second-line therapy or greater) in France (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top